Medicare contractor National Government Services finalizes local coverage determination for biomarker testing related to prostate cancer to include repeat biopsies and yearly testing Prostate cancer ...
MINNEAPOLIS, Sept. 23, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test ...
August 24, 2017 - Baltimore, Md. and Boston, Ma., Aug. 24, 2017 (GLOBE NEWSWIRE) -- CareFirst BlueCross BlueShield (CareFirst) and Exosome Diagnostics, Inc. (ExoDx) announced today that they have ...
Halfway through 5-year study, ExoDx Prostate Test offers more accurate stratification of high- and low-risk patients compared to standard of care MINNEAPOLIS, May 18, 2023 /PRNewswire/ -- Bio-Techne ...
Bio-Techne Corp. is expanding into the realm of diagnostics with its ExoDx Prostate cancer test and a development pipeline of comparable products — a new area of business for the company, best known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results